(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Solid Living Tips: Experiences from a Wellness Fan - 2Merz visit highlights new strategic, and strained, Germany-Israel bond
- 3The Best Traditional Music Arrangers in History
- 4Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- 5The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Best Food Truck Cooking: Decision in favor of Your Number one!
- Vote in favor of the field action that revives your psyche and soul!
- Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- 4 African Vacationer Locations
- Visual communication Programming for Fledglings
- Best Vegetarian Dinner: What's Your Plant-Based Pick?
- 7 Methods for further developing Rest Quality
- The Best Computer games Ever
- Disability rights activist and author Alice Wong dies at 51
